BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

653 related articles for article (PubMed ID: 31682743)

  • 1. Using Autoantibodies and Cutaneous Subset to Develop Outcome-Based Disease Classification in Systemic Sclerosis.
    Nihtyanova SI; Sari A; Harvey JC; Leslie A; Derrett-Smith EC; Fonseca C; Ong VH; Denton CP
    Arthritis Rheumatol; 2020 Mar; 72(3):465-476. PubMed ID: 31682743
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Registry of the Spanish network for systemic sclerosis: clinical pattern according to cutaneous subsets and immunological status.
    Simeón-Aznar CP; Fonollosa-Plá V; Tolosa-Vilella C; Espinosa-Garriga G; Ramos-Casals M; Campillo-Grau M; García-Hernández FJ; Castillo-Palma MJ; Sánchez-Román J; Callejas-Rubio JL; Ortego-Centeno N; Egurbide-Arberas MV; Trapiellla-Martínez L; Gallego-Villalobos M; Sáez-Comet L; Velilla-Marco J; Camps-García MT; de Ramón-Garrido E; Esteban Marcos EM; Pallarés-Ferreres L; Hidalgo-Tenorio C; Sabio-Sánchez JM; Gómez-de la Torre R; Salvador-Cervello G; Rios-Blanco JJ; Gil-Aguado A; Vilardell-Tarrés M
    Semin Arthritis Rheum; 2012 Jun; 41(6):789-800. PubMed ID: 22169458
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Prediction of pulmonary complications and long-term survival in systemic sclerosis.
    Nihtyanova SI; Schreiber BE; Ong VH; Rosenberg D; Moinzadeh P; Coghlan JG; Wells AU; Denton CP
    Arthritis Rheumatol; 2014 Jun; 66(6):1625-35. PubMed ID: 24591477
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Thinking outside the box--The associations with cutaneous involvement and autoantibody status in systemic sclerosis are not always what we expect.
    Srivastava N; Hudson M; Tatibouet S; Wang M; Baron M; Fritzler MJ;
    Semin Arthritis Rheum; 2015 Oct; 45(2):184-9. PubMed ID: 25959492
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Disease subsets, antinuclear antibody profile, and clinical features in 127 French and 247 US adult patients with systemic sclerosis.
    Meyer OC; Fertig N; Lucas M; Somogyi N; Medsger TA
    J Rheumatol; 2007 Jan; 34(1):104-9. PubMed ID: 17117486
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The Belgian Systemic Sclerosis Cohort: correlations between disease severity scores, cutaneous subsets, and autoantibody profile.
    Vanthuyne M; Smith V; De Langhe E; Van Praet J; Arat S; Depresseux G; Westhovens R; Blockmans D; Badot V; Cogan E; De Keyser F; Houssiau FA
    J Rheumatol; 2012 Nov; 39(11):2127-33. PubMed ID: 22984273
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Increased Frequency of Activated Switched Memory B Cells and Its Association With the Presence of Pulmonary Fibrosis in Diffuse Cutaneous Systemic Sclerosis Patients.
    Simon D; Balogh P; Erdő-Bonyár S; Böröcz K; Minier T; Czirják L; Berki T
    Front Immunol; 2021; 12():686483. PubMed ID: 34276673
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Improved survival in systemic sclerosis is associated with better ascertainment of internal organ disease: a retrospective cohort study.
    Nihtyanova SI; Tang EC; Coghlan JG; Wells AU; Black CM; Denton CP
    QJM; 2010 Feb; 103(2):109-15. PubMed ID: 19966313
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cutaneous Manifestations, Clinical Characteristics, and Prognosis of Patients With Systemic Sclerosis Sine Scleroderma: Data From the International EUSTAR Database.
    Lescoat A; Huang S; Carreira PE; Siegert E; de Vries-Bouwstra J; Distler JHW; Smith V; Del Galdo F; Anic B; Damjanov N; Rednic S; Ribi C; Bancel DF; Hoffmann-Vold AM; Gabrielli A; Distler O; Khanna D; Allanore Y;
    JAMA Dermatol; 2023 Aug; 159(8):837-847. PubMed ID: 37378994
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Systemic sclerosis sine scleroderma: a multicenter study of 1417 subjects.
    Diab S; Dostrovsky N; Hudson M; Tatibouet S; Fritzler MJ; Baron M; Khalidi N;
    J Rheumatol; 2014 Nov; 41(11):2179-85. PubMed ID: 25274885
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Autoantibody profile in a cohort of Algerian patients with systemic sclerosis.
    Tahiat A; Allam I; Abdessemed A; Mellal Y; Nebbab R; Ladjouze-Rezig A; Djidjik R
    Ann Biol Clin (Paris); 2020 Apr; 78(2):126-133. PubMed ID: 32175889
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Serological profile of patients with systemic sclerosis.
    Wielosz E; Dryglewska M; Majdan M
    Postepy Hig Med Dosw (Online); 2014 Aug; 68():987-91. PubMed ID: 25228505
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Autoantibody profiles in systemic sclerosis: predictive value for clinical evaluation and prognosis.
    Hamaguchi Y
    J Dermatol; 2010 Jan; 37(1):42-53. PubMed ID: 20175839
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Clinical characteristics and outcomes of 566 Thais with systemic sclerosis: A cohort study.
    Foocharoen C; Peansukwech U; Mahakkanukrauh A; Suwannaroj S; Pongkulkiat P; Khamphiw P; Nanagara R
    Int J Rheum Dis; 2020 Jul; 23(7):945-957. PubMed ID: 32420701
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Influence of clinical features, serum antinuclear antibodies, and lung function on survival of patients with systemic sclerosis.
    Jacobsen S; Ullman S; Shen GQ; Wiik A; Halberg P
    J Rheumatol; 2001 Nov; 28(11):2454-9. PubMed ID: 11708418
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Anti-U3 RNP autoantibodies in systemic sclerosis.
    Aggarwal R; Lucas M; Fertig N; Oddis CV; Medsger TA
    Arthritis Rheum; 2009 Apr; 60(4):1112-8. PubMed ID: 19333934
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Clinical differences between Thai systemic sclerosis patients with positive versus negative anti-topoisomerase I.
    Foocharoen C; Suwannachat P; Netwijitpan S; Mahakkanukrauh A; Suwannaroj S; Nanagara R;
    Int J Rheum Dis; 2016 Mar; 19(3):312-20. PubMed ID: 25293362
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Interstitial lung disease in systemic sclerosis: data from the spanish scleroderma study group.
    Sánchez-Cano D; Ortego-Centeno N; Callejas JL; Fonollosa Plá V; Ríos-Fernández R; Tolosa-Vilella C; Espinosa-Garriga G; Colunga-Argüelles D; Egurbide-Arberas MV; Rubio-Rivas M; Freire M; Ríos-Blanco JJ; Trapiella-Martínez L; Rodríguez-Carballeira M; Marín-Ballvé A; Pla-Salas X; Simeón-Aznar CP
    Rheumatol Int; 2018 Mar; 38(3):363-374. PubMed ID: 29322341
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Clinical risk assessment of organ manifestations in systemic sclerosis: a report from the EULAR Scleroderma Trials And Research group database.
    Walker UA; Tyndall A; Czirják L; Denton C; Farge-Bancel D; Kowal-Bielecka O; Müller-Ladner U; Bocelli-Tyndall C; Matucci-Cerinic M
    Ann Rheum Dis; 2007 Jun; 66(6):754-63. PubMed ID: 17234652
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A cross-sectional study of autoantibody profiles in the Waikato systemic sclerosis cohort, New Zealand.
    Chang WS; Schollum J; White DH; Solanki KK
    Clin Rheumatol; 2015 Nov; 34(11):1921-7. PubMed ID: 26022620
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 33.